An active metabolite of valganciclovir and an antiviral nucleoside derivative
Related Products
Alternative(s)
13853Ganciclovir
Labeled Version(s)
22565Ganciclovir-d5
Pro-drug Form(s)
13875Valganciclovir (hydrochloride)
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Ganciclovir (sodium salt)

Item No. 37487

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6H-purin-6-one, monosodium salt
CAS Number
107910-75-8
Synonyms
  • BW 759
  • DHPG
  • GCV
  • 9-(1,3-dihydroxy-2-propoxymethyl)Guanine
  • 2’-NDG
  • 2'-Nor-2'-deoxyguanosine
  • RS 21592
Molecular Formula
C9H12N5O4 • Na
Formula Weight
277.2
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: Slightly solubleDMSO: Slightly solubleEthanol: Slightly solublePBS (pH 7.2): 10 mg/ml
λmax
255 nm
SMILES
OCC(CO)OCN1C(N=C(N)N=C2[O-])=C2N=C1.[Na+]
InChi Code
InChI=1S/C9H13N5O4.Na/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16;/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17);/q;+1/p-1
InChi Key
JJICLMJFIKGAAU-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $43

    Add

    25 mg

    $73

    Add

    50 mg

    $161

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Ganciclovir is an active metabolite of the prodrug valganciclovir (Item No. 13875) and an antiviral nucleoside derivative of 2’-deoxyguanosine (Item No. 9002864).1,2 It reduces human, monkey, mouse, and guinea pig CMV replication in plaque reduction assays (EC50s = 1.3-70 µM).2 Topical application of ganciclovir (0.15%) decreases disease severity and corneal leukocyte infiltration in a cat model of ocular feline herpesvirus-1 (FHV-1) epithelial infection.3 Ganciclovir (15 mg/kg) prevents allograft histologic injury and natural killer (NK) and myeloid cell infiltration in a mouse model of murine CMV infection with renal transplantation.4 It induces tumor regression in a K-BALB murine sarcoma model using a mixed population of cells, which are positive or negative for expression of the gene encoding herpes simplex virus (HSV) thymidine kinase (TK).5 Formulations containing ganciclovir have been used in the treatment and prevention of CMV infections.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Carmichael, R.J., Whitfield, C., and Maxwell, L.K. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. J. Vet. Pharmacol. Ther. 36(5), 441-449 (2013).

    2. Freitas, V.R., Smee, D.F., Chernow, M., et al. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob. Agents Chemother. 28(2), 240-245 (1985).

    3. Ledbetter, E.C., Badanes, Z.I., Chan, R.X., et al. Comparative efficacy of topical ophthalmic ganciclovir and oral famciclovir in cats with experimental ocular feline herpesvirus-1 epithelial infection. J. Ocul. Pharmacol. Ther. 38(5), 339-347 (2022).

    4. Shimamura, M., Seleme, M.C., Guo, L., et al. Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage. Transplantation 95(1), 48-53 (2013).

    5. Freeman, S.M., Abboud, C.N., Whartenby, K.A., et al. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53(21), 5274-5283 (1993).